These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18617804)

  • 1. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
    Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
    Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid discharges from patients undergoing 131I treatments.
    Barquero R; Basurto F; Nuñez C; Esteban R
    J Environ Radioact; 2008 Oct; 99(10):1530-4. PubMed ID: 18243440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
    Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
    Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 131I effective half-life (Teff) for patients with thyroid cancer.
    Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
    Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
    Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
    Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 131I effective half-life and dosimetry in thyroid cancer patients.
    Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
    J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
    Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
    Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
    Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
    Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
    Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
    Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
    Al-Haj AN; Lagarde CS; Lobriguito AM
    Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide.
    Stabin MG
    J Nucl Med; 1993 Apr; 34(4):695-6. PubMed ID: 8455090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital discharge of patients with thyroid carcinoma treated with 131I.
    Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
    J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
    Modarresifar H; Almodovar S; Bass WB; Ojha B
    Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
    Marriott CJ; Webber CE; Gulenchyn KY
    Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation exposure to the family of radioactive patients.
    Harbert JC; Wells N
    J Nucl Med; 1974 Oct; 15(10):887-8. PubMed ID: 4418007
    [No Abstract]   [Full Text] [Related]  

  • 19. A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
    Traino AC; Di Martino F
    Phys Med Biol; 2006 Dec; 51(24):6449-56. PubMed ID: 17148828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.